TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs

Alexey V. Seregin, Nadezhda E. Yun, Allison L. Poussard, Bihung Peng, Jennifer K. Smith, Jeanon N. Smith, Milagros Salazar, Slobodan Paessler

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Junin virus (JUNV) is the etiological agent of the potentially lethal, reemerging human disease, Argentine hemorrhagic fever (AHF). The mechanism of the disease development is not well understood and no antiviral therapy is available. Candid 1, a live-attenuated vaccine, has been developed by the US Army and is being used in the endemic area to prevent AHF. This vaccine is only approved for use in Argentina. In this study we have used the alphavirus-based approach to engineer a replicon system based on a human (United States Food and Drug Administration Investigational New Drug status) vaccine TC83 that express heterologous viral antigens, such as glycoproteins (GPC) of Junin virus (JUNV). Preclinical studies testing the immunogenicity and efficacy of TC83/GPC were performed in guinea pigs. A single dose of the live-attenuated alphavirus based vaccine expressing only GPC was immunogenic and provided partial protection, while a double dose of the same vaccine provided a complete protection against JUNV. This is the first scientific report to our knowledge that the immune response against GPC alone is sufficient to prevent lethal disease against JUNV in an animal model.

Original languageEnglish (US)
Pages (from-to)4713-4718
Number of pages6
JournalVaccine
Volume28
Issue number30
DOIs
StatePublished - Jul 2010

Fingerprint

Junin virus
replicon
Replicon
guinea pigs
Guinea Pigs
Vaccines
vaccines
Alphavirus
live vaccines
lethal genes
Fever
immune response
Investigational Drugs
Heterophile Antigens
Attenuated Vaccines
Viral Antigens
new drugs
viral antigens
Argentina
etiological agents

Keywords

  • Animal models
  • Hemorrhagic fever
  • Immune response
  • Reemerging pathogens
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine
  • Medicine(all)

Cite this

Seregin, A. V., Yun, N. E., Poussard, A. L., Peng, B., Smith, J. K., Smith, J. N., ... Paessler, S. (2010). TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. Vaccine, 28(30), 4713-4718. https://doi.org/10.1016/j.vaccine.2010.04.077

TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. / Seregin, Alexey V.; Yun, Nadezhda E.; Poussard, Allison L.; Peng, Bihung; Smith, Jennifer K.; Smith, Jeanon N.; Salazar, Milagros; Paessler, Slobodan.

In: Vaccine, Vol. 28, No. 30, 07.2010, p. 4713-4718.

Research output: Contribution to journalArticle

Seregin, AV, Yun, NE, Poussard, AL, Peng, B, Smith, JK, Smith, JN, Salazar, M & Paessler, S 2010, 'TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs', Vaccine, vol. 28, no. 30, pp. 4713-4718. https://doi.org/10.1016/j.vaccine.2010.04.077
Seregin AV, Yun NE, Poussard AL, Peng B, Smith JK, Smith JN et al. TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. Vaccine. 2010 Jul;28(30):4713-4718. https://doi.org/10.1016/j.vaccine.2010.04.077
Seregin, Alexey V. ; Yun, Nadezhda E. ; Poussard, Allison L. ; Peng, Bihung ; Smith, Jennifer K. ; Smith, Jeanon N. ; Salazar, Milagros ; Paessler, Slobodan. / TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. In: Vaccine. 2010 ; Vol. 28, No. 30. pp. 4713-4718.
@article{f1a71a3a00684e1098c58e9db20f3ce3,
title = "TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs",
abstract = "Junin virus (JUNV) is the etiological agent of the potentially lethal, reemerging human disease, Argentine hemorrhagic fever (AHF). The mechanism of the disease development is not well understood and no antiviral therapy is available. Candid 1, a live-attenuated vaccine, has been developed by the US Army and is being used in the endemic area to prevent AHF. This vaccine is only approved for use in Argentina. In this study we have used the alphavirus-based approach to engineer a replicon system based on a human (United States Food and Drug Administration Investigational New Drug status) vaccine TC83 that express heterologous viral antigens, such as glycoproteins (GPC) of Junin virus (JUNV). Preclinical studies testing the immunogenicity and efficacy of TC83/GPC were performed in guinea pigs. A single dose of the live-attenuated alphavirus based vaccine expressing only GPC was immunogenic and provided partial protection, while a double dose of the same vaccine provided a complete protection against JUNV. This is the first scientific report to our knowledge that the immune response against GPC alone is sufficient to prevent lethal disease against JUNV in an animal model.",
keywords = "Animal models, Hemorrhagic fever, Immune response, Reemerging pathogens, Vaccine",
author = "Seregin, {Alexey V.} and Yun, {Nadezhda E.} and Poussard, {Allison L.} and Bihung Peng and Smith, {Jennifer K.} and Smith, {Jeanon N.} and Milagros Salazar and Slobodan Paessler",
year = "2010",
month = "7",
doi = "10.1016/j.vaccine.2010.04.077",
language = "English (US)",
volume = "28",
pages = "4713--4718",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "30",

}

TY - JOUR

T1 - TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs

AU - Seregin, Alexey V.

AU - Yun, Nadezhda E.

AU - Poussard, Allison L.

AU - Peng, Bihung

AU - Smith, Jennifer K.

AU - Smith, Jeanon N.

AU - Salazar, Milagros

AU - Paessler, Slobodan

PY - 2010/7

Y1 - 2010/7

N2 - Junin virus (JUNV) is the etiological agent of the potentially lethal, reemerging human disease, Argentine hemorrhagic fever (AHF). The mechanism of the disease development is not well understood and no antiviral therapy is available. Candid 1, a live-attenuated vaccine, has been developed by the US Army and is being used in the endemic area to prevent AHF. This vaccine is only approved for use in Argentina. In this study we have used the alphavirus-based approach to engineer a replicon system based on a human (United States Food and Drug Administration Investigational New Drug status) vaccine TC83 that express heterologous viral antigens, such as glycoproteins (GPC) of Junin virus (JUNV). Preclinical studies testing the immunogenicity and efficacy of TC83/GPC were performed in guinea pigs. A single dose of the live-attenuated alphavirus based vaccine expressing only GPC was immunogenic and provided partial protection, while a double dose of the same vaccine provided a complete protection against JUNV. This is the first scientific report to our knowledge that the immune response against GPC alone is sufficient to prevent lethal disease against JUNV in an animal model.

AB - Junin virus (JUNV) is the etiological agent of the potentially lethal, reemerging human disease, Argentine hemorrhagic fever (AHF). The mechanism of the disease development is not well understood and no antiviral therapy is available. Candid 1, a live-attenuated vaccine, has been developed by the US Army and is being used in the endemic area to prevent AHF. This vaccine is only approved for use in Argentina. In this study we have used the alphavirus-based approach to engineer a replicon system based on a human (United States Food and Drug Administration Investigational New Drug status) vaccine TC83 that express heterologous viral antigens, such as glycoproteins (GPC) of Junin virus (JUNV). Preclinical studies testing the immunogenicity and efficacy of TC83/GPC were performed in guinea pigs. A single dose of the live-attenuated alphavirus based vaccine expressing only GPC was immunogenic and provided partial protection, while a double dose of the same vaccine provided a complete protection against JUNV. This is the first scientific report to our knowledge that the immune response against GPC alone is sufficient to prevent lethal disease against JUNV in an animal model.

KW - Animal models

KW - Hemorrhagic fever

KW - Immune response

KW - Reemerging pathogens

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77954214468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954214468&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.04.077

DO - 10.1016/j.vaccine.2010.04.077

M3 - Article

VL - 28

SP - 4713

EP - 4718

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 30

ER -